Table 2 Disease activity, B-cell status, BAFF, and APRIL at all time points in patients with RA

Age (in years)/gender

38/F

73/M

60/F

64/F

60/F

66/F

63/F

60/F

58/M

DAS28

Baseline

6.78

8.14

5.69

5.81

7.69

6.48

7.4

n.d.

5.52

Depletion

4.42

5.43

n.d.

3.84

n.d.

n.d.

1.97

1.93

n.d.

6 months post-treatment

3.14

4.41

2.89

2.51

4.51

3.01

Percentage of CD19⁺ B cells

Baseline

1

4

4

8

7.6

1.7

6

9.6

7

Depletion

bdl

bdl

n.d.

bdl

bdl

bdl

bdl

bdl

bdl

6 months post-treatment

0.5

bdl

bdl

bdl

1

CD19⁺ B cells × 10⁹ per litre

Baseline

0.02

0.05

0.04

0.14

0.19

0.01

0.06

0.18

0.08

Depletion

bdl

bdl

n.d

bdl

bdl

bdl

bdl

bdl

bdl

6 months post-treatment

bdl

bdl

bdl

bdl

0.01

bdl

BAFF (ng/ml)

Baseline

1.01

3.42

0.92

0.75

1.33

1.31

1.90

2.30

1.08

Depletion

4.27

7.90

n.d.

2.62

n.d.

4.06

3.12

3.51

4.41

6 months post-treatment

5.88

6.34

4.46

2.83

1.59

APRIL (ng/ml)

Baseline

409

77.8

189

5.04

96.7

124

179

23.7

39.5

Depletion

412

54.3

n.d.

2.53

n.d.

112

160

38.2

61.7

6 months post-treatment

419

32.0

113

1.12

97.1